Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
“I am proud of Frank for earning a second placement among Houston’s Top 25 CFOs,” said
Stokes has served as Castle’s chief financial officer since
The comprehensive list of the Top 25 CFOs of
About
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of
About TOP CFOs
TOP CFOs (formerly Finance & Investing) is a comprehensive source for research and information, business news, and corporate actions related to banking, finance, public and private markets, and other topics relevant to CFOs. Based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410056539/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: